Sotylize is owned by Azurity.
Sotylize contains Sotalol Hydrochloride.
Sotylize has a total of 3 drug patents out of which 0 drug patents have expired.
Sotylize was authorised for market use on 22 October, 2014.
Sotylize is available in solution;oral dosage forms.
Sotylize can be used as sotylize is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently in sinus rhythm, sotylize is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently in sinus rhythm; indicated for the treatment of ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgement of the physician are life-threatening.
The generics of Sotylize are possible to be released after 31 August, 2035.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10206895 | AZURITY | Sotalol compositions and uses of the same |
Apr, 2034
(10 years from now) | |
US11013703 | AZURITY | Sotalol compositions and uses of the same |
Apr, 2034
(10 years from now) | |
US9724297 | AZURITY | Sotalol compositions and uses of the same |
Aug, 2035
(12 years from now) |
Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient
Market Authorisation Date: 22 October, 2014
Treatment: Sotylize is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently ...
Dosage: SOLUTION;ORAL
5
United States
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic